| AlloVir is a late clinical-stage cell therapy company developing allogeneic T-cell therapies to treat and prevent viral diseases. Co.'s key product candidate, Viralym-M, is a multi-VST therapy targeting five viruses: BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, and human herpesvirus 6. ALVR106 is Co.'s second multi-virus-targeted off-the-shelf VST product candidate that it developed to target respiratory diseases. ALVR109 is an allogeneic, off-the-shelf single virus-targeted cell therapy designed to target SARS-CoV-2. Co. is also developing ALVR107 designed to target hepatitis B, or HBV, infected cells and treat chronic HBV infections and ALVR108 to treat human herpesvirus-8. We show 6 historical shares outstanding datapoints in our coverage of ALVR's shares outstanding history.|
Understanding the changing numbers of ALVR shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like ALVR versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching ALVR by allowing them to research ALVR shares outstanding history
as well as any other stock in our coverage universe.